Share Price Drop

Showing 3002 articles
Business

AbCellera Biologics: A Tale of Two Valuations Amid Steep Share Decline

Shares of antibody discovery firm AbCellera Biologics plunged 16.8% last week, reigniting debate over its true worth. While a discounted cash flow model suggests deep undervaluation, its sky-high price-to-sales ratio paints a starkly different picture, leaving investors to navigate conflicting signals in a volatile biotech market.

Business

Barclays Shares Surge 68% in a Year: Is the Rally Justified?

Barclays' stock has delivered a stellar 68% total return to shareholders over the past year, fueled by strong revenue and profit figures. As the share price approaches analyst targets, investors are weighing whether the current valuation still offers value or if the easy gains have been made.

Business

Gap's Stock Surge: Is the Turnaround Story Already Priced In?

Gap's shares have soared over 100% in three years, fueled by a remarkable operational turnaround. But as the stock hovers near $28, investors are asking: does the current price fairly reflect the future, or has the market run ahead of itself? A deep dive into valuation metrics reveals a mixed picture.